Hsv 1 and 2 Gowey Protocol Versus Placebo

Phase II Clinical Trial of Versabase/Sarracenia Purpurea Versus Placebo

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01477879

Enrollment

Registered

2011-11-23

Start date

2011-01-31

Completion date

2011-03-31

Last updated

2011-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes

Brief summary

This study will compare efficacy of versabase gel with 20% sarracenia purpurea versus placebo applied every 3-4 hours to herpes lesions.

Detailed description

Patients screened for hsv one or two. Patients with herpes given a 1/8 oz of gel. Researcher does not know which is active and which is placebo (placebo is actually just versabase gel). Patent applies gel to lesions every 3-4 hours. Returns to clinic on days 3, 5, and 14 for evaluation. Up to 50 patients may be enrolled.

Interventions

OTHERVersabase gel with sarracenia purpurea 20% liquid extract

Topical application of gel/plant mix to lesions

OTHERplacebo (versabase gel only)

versabase gel only

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

\- Hsv 1&2

Exclusion criteria

* No active lesions

Design outcomes

Primary

Measure	Time frame	Description
Pain	2 weeks	Pain scale-- subjective
Size	2 weeks	Measure lesion size over 2 weeks

Secondary

Measure	Time frame	Description
Appearance	2 weeks	Photo taken of lesion w patient informed consent

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026